SOLO-2

Following the SOLO-2 trial results surpassing expectations, Wedbush’s David Nierengarten stated that the data demonstrated “similar top-line efficacy for Lynparza as that achieved by niraparib in the NOVA study.” The analyst reiterated an Outperform rating on TESARO Inc (NASDAQ:...